Long-Term Outcomes of Scleroderma Renal Crisis PDF Print E-mail
Wednesday, 17 March 2010 13:59
Virginia D. Steen, MD, and Thomas A. Medsger Jr., MD
Published: October 17th, 2000

Background: Although scleroderma renal crisis, a complication of systemic sclerosis, can be treated with angiotensin-converting enzyme (ACE) inhibitors, its long-term outcomes are not known.

Objective: To determine outcomes, natural history, and risk factors in patients with systemic sclerosis and scleroderma renal crisis.

Design: Prospective observational cohort study.

Setting: University program specializing in scleroderma.

Patients: 145 patients with scleroderma renal crisis who received ACE inhibitors and 662 patients with scleroderma who did not have renal crisis.

Measurements: Among patients with renal crisis, the four outcomes studied were no dialysis, temporary dialysis, permanent dialysis, and early death. Demographic, clinical, and laboratory data were compared to identify risk factors for specific outcomes. Follow-up was 5 to 10 years.

Results: 61% of patients with renal crisis had good outcomes (55 received no dialysis, and 34 received temporary dialysis); only 4 of these (4%) progressed to chronic renal failure and permanent dialysis. More than half of the patients who initially required dialysis could discontinue it 3 to 18 months later. Survival of patients in the good outcome group was similar to that of patients with diffuse scleroderma who did not have renal crisis. Some patients (39%) had bad outcomes (permanent dialysis or early death). Conclusions: Renal crisis can be effectively managed when hypertension is aggressively controlled with ACE inhibitors. Patients should continue taking ACE inhibitors even after beginning dialysis in hopes of discontinuing dialysis.

Scleroderma renal crisis (1) is defined as the new onset of severe hypertension associated with a rapid increase in serum creatinine concentration, microangiopathic hemolytic anemia, or both. Outcomes of this disorder, a once-fatal complication of scleroderma, have dramatically improved with the use of angiotensin-converting enzyme (ACE) inhibitors (1). We examined short- and long-term outcomes
of renal crisis in patients taking these medications...

To continue reading the full article, please login in and download from the link provided below.

 
More articles :

» Digital Ulcers Linked to More Severe Systemic Sclerosis

Digital ulcers are associated with more severe systemic sclerosis (SSc) disease, including skin and lung involvement, but not with pulmonary arterial hypertension (PAH) or scleroderma renal crisis (SRC), according to research published in the...

» Cancer Risk Among Patients With Systemic Sclerosis: A Nationwide Population Study In Taiwan

C-F Kuo, S-F Luo, K-H Yu, I-J Chou, W-Y Tseng, H-C Chang, Y-F Fang, M-J Chiou, L-C SeePosted online on December 11, 2011Objectives: Systemic sclerosis (SSc) has been associated with high cancer risk. We compared the cancer risk among SSc patients...

» A New Marker of Silent Cardiovascular Disease in Diffuse Scleroderma

Patients with diffuse systemic sclerosis (SSc) and no clinical evidence of (CVD) may, in fact, have subclinical CVD and , and it is detectable. This is the conclusion of a small pilot study from Italy, which showed that elevated plasma levels of ...

» Survival In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc) and one of the leading causes of morbidity and mortality in this disease. Although several recent studies have suggested an improvement in the prognosis of...

» Placebo-controlled Study of Methotrexate in Juvenile Localised Scleroderma

According to the results of this placebo-controlled study, is an effective treatment for juvenile localised scleroderma (JLS). The authors note that JLS is a chronic progressive fibrotic process of the skin causing permanent disability and...

» Mechanism ID’d for Benefit of Stem Cells in Autoimmunity

Bone marrow mesenchymal stem cells (BMMSCs) activate a mechanism involving coupling of FAS/FAS ligand to induce T cell apoptosis and immune tolerance, according to an experimental study published online April 26 in Cell Stem Cell.To investigate the...